Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care.
Ward
Michael M
MM
D000911:Antibodies, Monoclonal / Q000191:economics*; D019985:Benchmarking; D001685:Biological Factors / Q000191:economics*; D006801:Humans; D000069285:Infliximab; D016345:Medicare Part B / Q000191:economics; D054524:Medicare Part D / Q000191:economics*; D012052:Reimbursement, Incentive; D014481:United States
D000911:Antibodies, Monoclonal; D001685:Biological Factors; D000069285:Infliximab
Cancer. 2007 Nov 15;110(10):2304-12
17924373
Arthritis Rheum. 2009 Jun 15;61(6):745-54
19479704
Arthritis Care Res (Hoboken). 2010 Mar;62(3):354-61
20391481
N Engl J Med. 2003 Apr 17;348(16):1590-7
12700381
Arthritis Rheum. 2008 Apr;58(4):939-46
18383356
Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-152-W5-166
15840625
Health Aff (Millwood). 2007 Sep-Oct;26(5):w630-43
17711865
Am J Manag Care. 2003 Oct;9(6 Suppl):S136-43
14577718
Am J Health Syst Pharm. 2006 May 1;63(9 Suppl 2):S18-21
16641253
JAMA. 2008 Jul 9;300(2):189-96
18612116
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229
17049139
Arch Intern Med. 2006 Jan 9;166(1):57-63
16401811